SAN DIEGO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Richtech Robotics Inc. (NASDAQ: RR) publicly traded securities between January 27, 2026 and 12:00 p.m. EST on January 29, 2026, inclusive (the "Class Period"), have until April 3, 2026 to seek appointment as lead plaintiff of the Richtech Robotics class action lawsuit. Captioned Diez v. Richtech Robotics Inc., No. 26-cv-00231 (D. Nev.), the Richtech Robotics class action la ...

Core Insights - Gartner forecasts annual revenue and earnings below Wall Street expectations due to reduced enterprise spending impacting demand for consulting services [1] Group 1 - The company anticipates a decline in revenue and earnings, indicating a challenging market environment [1] - Enterprises are scaling back their spending, which is a significant factor affecting demand for Gartner's consulting services [1]

Core Insights - The price of gold has surged 175% since January 30, 2023, following a modest 8% increase from 2013 to 2022, indicating a significant shift in investor sentiment towards gold as a safe-haven asset [1] - Bitcoin, while historically impressive with a 22,770% increase over the past decade, has underperformed against gold in the last 12 and 24 months, currently sitting 33% below its peak [2][7] Investment Trends - Investment professionals advocate for gold as a safe-haven asset during periods of uncertainty due to its lack of correlation with other asset classes, limited supply, and neutral characteristics, which have contributed to its strong performance recently [3] - Central banks globally are increasing their gold reserves to reduce dependence on the U.S., with the value of gold held by these banks now exceeding their U.S. Treasury balances [6] Market Dynamics - The U.S. is experiencing significant trade deficits and a record federal debt of $39 trillion, alongside a depreciating dollar, which has fallen to its lowest level in four years against major currencies, further bolstering gold's appeal [5] - Bitcoin's recent performance suggests it remains a risk-on asset, indicating that it has yet to fully transition into a widely accepted store of value, which may require broader institutional adoption, including acceptance by central banks [7][8] Future Outlook - Despite short-term trends that may discourage Bitcoin investors, there is a belief that Bitcoin possesses substantial upside potential due to its scarcity compared to gold and its digital nature, presenting a buying opportunity during dips [9]

Diamond Hill Capital, an investment management company, released its “Large Cap Fund” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. Equity markets continued their upward momentum in Q4, with the Russell 1000 Value Index increasing 3.8%. The information technology (+11%) and communication services (+9%) sectors are leading the rally, driven by AI optimism. The growth areas of the market accounted for the majority of the Index’s return in Q4. The firm maintains a cautious s ...

Core Insights - Ashland Global Holdings Inc. reported a loss from continuing operations of $14 million or 30 cents per share for Q1 fiscal 2026, an improvement from a loss of $166 million or $3.51 per share in the same quarter last year [1] - Adjusted earnings were 26 cents per share, slightly down from 28 cents in the prior year, but exceeded the Zacks Consensus Estimate of 23 cents [1] Financial Performance - Sales decreased by 5% year over year to $386 million, missing the Zacks Consensus Estimate of $408.3 million [2] - The decline in sales was attributed to the divestiture of the Avoca business, which reduced revenue by approximately $10 million, and weaker demand in sectors such as coatings, construction, personal care, and industrials, along with modest pricing pressure [2] Segment Performance - Life Sciences segment sales increased by 4% year over year to $139 million, though it fell short of the Zacks Consensus Estimate of $146 million, driven by resilient demand in pharma applications [3] - Personal Care segment sales declined by 8% year over year to $123 million, missing the Zacks Consensus Estimate of $132 million, primarily due to portfolio optimization linked to the Avoca divestiture [4] - Specialty Additives segment sales fell by 11% year over year to $102 million, missing the Zacks Consensus Estimate of $111 million, due to weak demand in coatings in China and increased competition [5] - Intermediates segment sales decreased by 6% year over year to $31 million, slightly beating the consensus estimate of $30.26 million, mainly due to lower pricing across the BDO value chain [6] Financial Position - Cash and cash equivalents at the end of the quarter were $304 million, reflecting a sequential increase of approximately 41.4% [7] - Long-term debt stood at $1,387 million, up roughly 0.2% from the previous quarter [7] Outlook - For fiscal 2026, Ashland anticipates sales between $1.835 billion and $1.905 billion, with adjusted EBITDA projected at $400 million to $420 million [8] - Adjusted EPS is expected to show double-digit growth due to operating improvements and portfolio optimization, with free cash flow conversion targeted at around 50% of adjusted EBITDA and capital expenditure estimated at about $100 million [8]

across television, digital and social media. The new TV spot features Cedric in a...## Plant Lovers Rejoice! Zevo Launches Two New Innovations to Defend Your Home & Houseplants From BugsCINCINNATI-- ([BUSINESS WIRE])--As the temperatures drop and you bring your hosting, and plants, inside - bugs can find their way in too, often drawn to the same houseplants you love. Thankfully, Zevo is expanding their line of worry-free pest solutions with the launch of Zevo Plant Flying Insect Trap and Zevo Trap+Kill Foam ...

With Brent crude trading in the $65–$70 corridor and a 2.3 million barrels per day (bpd) global surplus pressuring prices, Igor Isaev, Doctor of Technical Sciences and Head of Analytics at Mind Money,... ...

Diamond Hill Capital, an investment management company, released its “Large Cap Fund” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. Equity markets continued their upward momentum in Q4, with the Russell 1000 Value Index increasing 3.8%. The information technology (+11%) and communication services (+9%) sectors are leading the rally, driven by AI optimism. The growth areas of the market accounted for the majority of the Index’s return in Q4. The firm maintains a cautious s ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Insights - Rigel Pharmaceuticals has appointed Michael P. Miller to its Board of Directors, bringing over 40 years of experience in the biotechnology and pharmaceutical industries [1][2]. Company Overview - Rigel Pharmaceuticals, Inc. is a biotechnology company focused on discovering, developing, and providing novel therapies for patients with hematologic disorders and cancer [3]. - The company was founded in 1996 and is based in South San Francisco, California [3]. Leadership Appointment - Michael P. Miller's appointment is expected to enhance Rigel's strategic plan, particularly in growing its current portfolio and exploring in-licensing opportunities [2]. - Miller has held significant roles in various companies, including Executive Vice President of U.S. Commercial at Jazz Pharmaceuticals and Senior Vice President at Vivus [2]. Strategic Vision - Miller expressed enthusiasm about joining Rigel, highlighting the company's evolution into a profitable entity with a strong commercial engine that supports a promising development pipeline [3]. - The focus will be on serving more patients with hematologic disorders and cancer, aligning with Rigel's mission [3].